G H DEFICIENCY is associated with extreme short stature, central adiposity, delayed skeletal maturation, and vulnerability to fasting hypoglycemia. Current limitations of therapy are the requirement for frequent administration of hormone and a decreased responsiveness to treatment with time.
The growth-promoting effects of GH on dwarf and normal rodents (l-5) are well documented. Although there is some evidence that pulsatile delivery achieves greater short term growth responses than continuous infusion (6-8) in rodents, either method of delivery is more effective than daily injection. (8, 9) . There is evidence to suggest that this may also be the case in humans. (10-13). As the therapeutic effects of the recombinant protein are hampered by its short half-life in the bloodstream, the rat GH (rGH) complementary DNA (cDNA) was introduced into dwarf mice in vivo using adenovirus-mediated gene transfer. rGH was chosen because rGH and mouse GH are highly conserved (>90% in the mature protein) (14, 15) , and antibodies are 'available that allow rGH to be measured in serum. Expression of the rGH cDNA was controlled by the human elongation factor-la (EFla) promoter. This promoter has been shown to confer high level constitutive expression in many cell and tissue types in vitro (16) and in vivo. (17) EFla catalyzes the GTP-dependent binding of aminoacyl transfer RNA to the A site of the ribosome during the elongation phase of protein synthesis.
The little strain of mice mimics GH deficiency in humans. The mutation occurred in the C57BL / 6J inbred strain of mice at the Jackson Laboratory (Bar Harbor, ME) (18). The lit mutation, a single nucleotide substitution that alters codon 60 of the GH-releasing factor receptor (19, 20) , is inherited in an autosomal recessive manner. Lit/lit dwarf animals exhibit reduced serum concentrations of GH, insulin-like growth factor I (IGF-I), and IGF-binding protein-3 (IGFBP-3) and reduced body weight and length. They also have lower blood glucose and serum insulin levels. The alterations in body composition associated with GH deficiency are reproduced in this dwarf strain of mice (21) as well.
The replication-defective recombinant adenovirus has a number of features that make it an effective tool to deliver therapeutic genes in vivo. Adenovirus can be produced and purified in a concentrated form that facilitates in vivo delivery. Potential oncogenic effects resulting from viral integration into critical chromosomal regions are unlikely because adenoviruses do not integrate into host chromosome DNA. Efficient adenoviral infection and gene expression is not dependent upon target cell proliferation. Although adenovirus exhibits a natural tropism for respiratory epithelium, recombinant adenoviral vectors also infect other epithelial-derived tissues and other nonproliferative cells as well (22) (23) (24) (25) . Previous studies have shown that the majority of the virus is localized in the liver when adenovirus is delivered by intraportal (26, 27) or tail vein (28-30) injection. We speculated that ectopic expression of GH in the liver, a major site of GH action, might decrease the level of expression required for therapeutic efficacy and thereby decrease potential side-effects associated with high level GH expression (31, 32) .
The goal of this study was to determine whether constitutive expression of GH in the liver after adenovirus-mediated gene transfer could correct the dwarf phenotype of little mice. Two doses of the recombinant adenovirus were injected into dwarf mice, and the resulting plasma GH concentrations were determined. The ability of the dose leading to GH concentrations in the desired range to correct the dwarf phenotype was then compared to nonspecific effects induced by injection of the same dose of a recombinant adenovirus encoding human cY,-antitrypsin (hAAT). 
Animals

Results
Serum rGH levels after systemic delivery of recombinant GH adenovirus
When the recombinant adenoviral vector was injected in lit/lit mice at a dose of 10' plaque-forming units (pfu) or more, high levels of GH were detected in serum for at least 7 weeks (Fig. 1) . A viral dose of 10s pfu led to an initial peak serum GH level of 1900 pg/liter, which then decreased to -125 Fg/liter during the next 2 weeks and remained at that level for the duration of the experiment. A viral dose of lo9 pfu induced a serum GH level of -35,000 pg/liter, which then decreased to -2500 pg/liter over the next 2 weeks and stabilized at 1000 pg/liter for the duration of the study. The decrease in GH expression is in part due to the host immune system's ability to recognize and subsequently eliminate the virally transduced cells (26, 38, 39) . A dose of 10' pfu / mouse was chosen as the therapeutic dose for all subsequent studies. Animals in both groups continued to gain weight throughout the study and showed no apparent ill effects due to ectopic GH expression.
Serum IGF-I expression in response to recombinant GH or AAT adenovirus treatment
The effects of administration of lo8 pfu recombinant GH adenovirus or control hAAT adenovirus on serum IGF-I levels were determined (Fig. 2) . IGF-I levels in lit/lit mice treated with the GH adenovirus were significantly higher (238 + 55 rig/ml) than those in animals injected with the recombinant hAAT adenovirus (61 t 17 ng/ ml) within 3 weeks after virus injection and remained elevated for the remainder of the study.
Fasting blood glucose and serum insulin in response to recombinant GH or AAT adenovirus treatment Enhanced GH expression tended to increase both fasting blood glucose and insulin levels (Fig. 3) . However, the group size was insufficient to demonstrate significant differences. Fasting blood glucose levels were intermediate between those in lit/lit animals treated with the recombinant hAAT virus and those in age-matched lit / + animals. Fasting serum insulin levels in GH-treated animals were comparable to those in age-matched lit/ + animals.
Phenotypic response to recombinant GH or AAT adenovirus treatment
Linear growth. The effects of GH expression on linear growth were also determined ( Table 1) . Administration of the recombinant hAAT virus had no growth-promoting effect on body length. However, administration of the GH adenovirus induced linear growth. Lit/lit animals treated with the recombinant rGH adenovirus attained a body length indistinguishable from that of age-matched lit/ + animals within 7 weeks after treatment.
Body weight. At the time of virus administration, lif/lif animals
Body composition. The effects of GH and AAT expression on were significantly smaller (Fig. 4) animals (10.9 us. 20.0 g). Administration of the recombinant hAAT adenovirus had little effect on body weight over the 7 weeks following virus administration (11.42 VS. 11.93 g). Administration of the GH adenovirus induced rapid weight gain (10.4 VS. 21.7 g), such that normal body weight was achieved by 5 weeks after treatment. treated with the recombinant hAAT adenovirus had significantly lower body water and protein but higher body fat compared to age-matched lit/ + animals. Treatment of lit/lit animals with the recombinant rGH adenovirus normalized body composition by reducing body fat and increasing body water and protein.
Orgnn weight. There was a statistically significant increase in the liver and kidney weights of animals treated with ad.EF/ rGH compared to those of lit/ + animals (4.9% US. 3.7% and 0.76% US. 0.65%, respectively) even after normalization for differences in body weight (Table 3) . No effect was seen on spleen, heart, or lung. Animals treated with the hAAT adenovirus had organ weights comparable to those of agematched lit / + animals.
Discussion
GH, like most other pituitary hormones, normally is secreted in a pulsatile fashion (40-42). For certain pituitary hormones, including LH and FSH, pulsatile delivery is an absolute requirement to achieve optimal physiological effects (43). Less is known about GH's requirement for pulsatility. Several previous studies have examined the somatropic effects of continuous GH delivery (6-13) and suggest that short term continuous hormone administration is capable of effecting growth. Other studies have examined IGF-I responses to various modes of GH delivery and indicate that continuous administration is as effective as pulsatile delivery in humans (10). Several investigators have attempted to use gene delivery to induce constitutive GH expression (1, 44-46) with limited success due to the low levels of expression achieved. In the current study, the level of GH expression used restored circulating concentrations of IGF-I to a level comparable to those of normal animals growing at a similar rate. Furthermore, these data indicate that somatic and organ growth can be restored with minimal side-effects by constitutive GH expression and continuous GH exposure over a 7-week period in dwarf mice.
In light of the selective growth seen in transgenic animals expressing GH and the endogenous serum GH levels in dwarf and normal mice (47-49), we anticipated that sustained GH expression of 100-300 pg/liter would be sufficient to correct the growth failure in lit/lit mice. A doseresponse curve was carried out to determine a viral dose that would result in persistent GH expression in this range. Administration of a viral dose of lo8 pfu led to constitutively elevated serum GH levels in the desired range with no apparent acute side-effects. Therefore, lo8 pfu/mouse was chosen to induce sustained serum GH levels of -200 PcLg / L. The effects of the enhanced GH expression induced by the recombinant GH adenovirus, ad.EF/ rGH, were compared to nonspecific effects elicited by the same dose of an adenovirus encoding hAAT. Age-matched lit/ + animals served as a point of reference. Lit/lit animals injected with ad.EF/rGH had peak serum GH levels of 1000 kg/ liter within 4 days after administration of the recombinant adenovirus. Serum GH levels subsequently decreased to -200 pg/ liter and stabilized at that level for the remainder of the study. This enhanced GH expression caused an increase in IGF-I expression. Although serum GH levels increased dramatically within the first few days after administration of the GH adenovirus, serum IGF-I levels did not increase as quickly. This may in part be due to reduced IGFBP-3 levels in GHdeficient humans and animals (50). As IGFBP-3, the major serum carrier protein for IGF-I, is GH dependent, a longer period of GH exposure may be required to increase IGFBP-3 and thereby stabilize IGF-I levels in serum.
Lit/lit animals injected with the recombinant GH adenovirus exhibited enhanced growth, measured as weight gain and overall body length. Constitutive GH expression induced an accelerated growth rate, so that body weight was normalized within 5 weeks after treatment. Total body length also increased dramatically in response to enhanced GH expression.
Enhanced GH expression also had significant effects on body composition. GH expression caused a significant increase in body water and protein and a decrease in total body fat compared to those values in lit/lit animals treated with the recombinant hAAT adenovirus. The body composition of lit/lit animals treated with the recombinant rGH adenovirus is equivalent to that of normal age-matched lit/ + animals. Chronic exposure to high levels of GH can result in both hyperglycemia and insulin resistance (31,51). In the current study, enhanced GH expression tended to increase both fasting blood glucose and insulin levels. However, the group size was insufficient to demonstrate significant differences. Blood glucose levels were intermediate between those seen in lit/lit animals treated with the recombinant hAAT virus and agematched lit/ + animals. Serum insulin levels in GH-treated animals were comparable to those in lit/ + animals. Thus, insulin resistance was not a consequence of ectopic GH expression in this study.
Hepatic and renal hyperplasia and hypertrophy also are well described in response to prolonged high level GH exposure (31, 32). In the current study, lit/lit animals treated with the EF/rGH virus exhibited slight, but significant, increases in liver and kidney sizes. The impact, if any, of GHinduced hypertrophy on liver and kidney function may warrant investigation in the future.
GH has profound physiological effects on many pathological states, and its utility has been examined extensively in children with various forms of hypopituitarism, renal failure-induced growth retardation, and Turner's syndrome. Unresolved issues remain with regard to the safety and efficacy of recombinant GH treatment in GH-sufficient patients. Such risks and benefits can be evaluated by our gene transfer-based approach to introducing rGH into laboratory animals.
In conclusion, these findings support the hypothesis that the dwarf phenotype in the GH-deficient lit/lit mouse can be corrected by constitutive expression of GH achieved through in uizm gene delivery. Furthermore, these data indicate that correction of GH insufficiency by gene transfer may someday represent an alternative treatment option to current modes of GH delivery. 
